Twelfth of the "ASCO Direct™ China" webinar series: Immunotherapies for Lymphoma Treatment

About this Event

Webinar Date:

  • China Time: Saturday September 26th, 9:00AM
  • US EST Time: Friday, September 25th, 9:00PM
  • US PST Time: Friday, September 25th, 6:00PM

Conference Language: English

Venue: Live Zoom Webinar

Webinar Agenda

Chairs:

  • Dr. John Kuruvilla, Medical Oncologist, Department of Medicine, University of Toronto; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
  • Dr. Huiqiang Huang, Medical Oncology, Sun Yat-sen University Cancer Center

Presentations:

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL)

  • Dr. John Kuruvilla, Medical Oncologist, Department of Medicine, University of Toronto; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre

Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era?

  • Dr. Nirav Shah, Medical Oncologist, Medical College of Wisconsin

Applications of NGS in clinical practices in lymphoma

  • Dr. Wei Xu, Department of Hematology, The First Affiliated Hospital with Nanjing Medical University

Panel Discussion

Chairs

  • Dr. John Kuruvilla, Medical Oncologist, Department of Medicine, University of Toronto; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
  • Dr. Huiqiang Huang, Medical Oncology, Sun Yat-sen University Cancer Center

Guests

  • Dr. Nirav Shah, Medical Oncologist, Medical College of Wisconsin
  • Dr. Wei Xu, Department of Hematology, The First Affiliated Hospital with Nanjing Medical University
  • Dr. Jie Jin, Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine
  • Dr. Wenyu Li, Department of Lymphoma, Guangdong General Hospital
  • Dr. Qingqing Cai, Department of Internal Medicine, Sun Yat-sen University Cancer Center
  • Dr. Yan Xie, Department of Lymphoma, Beijing Cancer Hospital

Speakers and Panelists Bio

                        

Dr. John Kuruvilla, Medical Oncologist, Department of Medicine, University of Toronto; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre

Dr. John Kuruvilla is an Associate Professor of Medicine at the University of Toronto and a Clinical Investigator in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto. He is a hematologist and member of the Lymphoma and the Autologous Blood and Marrow Transplant programs at Princess Margaret.

Dr. Kuruvilla’s research interest is the development of novel therapeutics in lymphoid malignancies and incorporating translational research into clinical trials. He is the Lymphoma Co-Chair for the Canadian Cancer Trials Group (CCTG) as well as the Chair of the Scientific Advisory Board of Lymphoma Canada.

                       

Dr. Huiqiang Huang, Medical Oncology, Sun Yat-sen University Cancer Center

Hui-qiang Huang MD, PhD graduated from Sun Yat-sen University of Medical Sciences in 1984. and received Master Degree and Doctorate Degree in 1990 and 1998 respectively in SYSUCC. Currently he is Deputy-Chief of the Department of Medical Oncology, Sun Yat-Sen University Cancer Center(SYSUCC) and Professor and a Tutor of Doctoral Degree, Clinical Oncology in SYSUCC. He is now the Chairman of Chinese Aging Well Association ,Lymphoma Committee (CAWAL), the Deputy Chairman of Union of China Lymphoma investigators . Within the Chinese Association of Anti-Cancer ( CACAV), Dr. Huang is the Deputy Director of Lymphoma, as well as Director of Junior Lymphoma Physician, CACA, and a Director , Committee of Hematologic Malignancy, Association for Anti-Cancer of Guangdong Province , CACA, and a Deputy Director of Committee of Lymphoma, Association for Anti-Cancer , Guangdong Province, CACA. And he is also a Deputy Director, Institute of Hematologic diseases of Sun Yat-sen University (SYSU). He serves on the Editorial Review Board of Chinese Journal of Cancer, Leukemia/lymphoma (China) and Journal of SUN YAT-SEN University (Medical Sciences). He is now focusing on basic research and clinical study on malignant lymphoma especially on new therapeutic strategy for NK/T lymphoma and actively involved in autologous hematopoietic progenitor cell transplantation for aggressive relapsed or refractory lymphomas. He also gave oral presentations about P-Gemox for newly diagnosed or relapsed/refractory NK/TCL and other topics in 2013 ASH meeting ,2014 - 2019 T Cell Lymphoma Forum( TCLF,USA ) ,2015,2018 Italian T Cell lymphoma Forum as well as 2015, 2017and 2019 Lugano ICML respectively. His paper about EPOCH in the treatment of NK/T lymphoma was recommended by 2009-2010 NCCN Guideline. P-Gemox ( Gelox ) both for NK/TCL early and advanced was also recommended by 2016-2017 NCCN Guideline . He has conducted as Principal Investigator or participant in many Global or National clinical trials . Dr. Huang has authored over 100 peer-reviewed articles including the New England Journal of Medicine (2015,second author) , Nature Medicine (2018 Co-corresponding author ) and Lancet Oncology ( 2108 co-first author , 2020 co-corresponding author).

                      

Dr. Nirav Shah, Medical Oncologist, Medical College of Wisconsin

Nirav Shah, MD, MSHP, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015.

                       

Dr. Wei Xu, Department of Hematology, The First Affiliated Hospital with Nanjing Medical University

  • Graduated from Nanjing Medical University in 1990
  • Holds the position of Professor of the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
  • Focused on the clinical and biologic characteristics of lymphoproliferative disease

                    

Dr. Jie Jin, Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine

  • Director, Zhejiang Provincial Key Laboratory of Diagnosis and Treatment for Hematological Malignancies
  • Director, Department of Hematology, Zhejiang University School of Medicine
  • Principal investigator, Department of Hematology (National Key Clinical Discipline of the Ministry of Health), The First Affiliated Hospital of Zhejiang University School of Medicine
  • Team Leader, Leukemia Basic and Clinical Research Key Innovation Team of Zhejiang Province
  • Principal investigator, Hematology, Zhejiang Provincial Department of Health
  • Recipient, State Council Special Allowance
  • Recipient, Advanced Worker of National Health System
  • Recipient, Young and middle-aged experts with outstanding contributions in Zhejiang Province
  • Recipient, Outstanding Physician Award, Zhejiang Province
  • Recipient, Good Doctor Award, Zhejiang University
  • Member, the 7th and 9th Standing Committees of the Chinese Society of Hematology, Chinese Medical Association
  • Deputy Head of the Red Blood Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association
  • Member, Chinese Society of Experimental Hematology Standing Committee
  • Chairman, Hematology Committee of the China Medical Women’s Association (CMWA)
  • Chairman, Translational Hematology Committee, Chinese Anti-Cancer Association
  • Vice Chairman, Chinese Society of Clinical Oncology (CSCO) Anti-leukemia Committee
  • Member, CSCO Anti-lymphoma Standing Committee
  • President, Zhejiang Society of Hematology, Zhejiang Medical Association

Professor Jin has published more than 190 SCI papers. She is the corresponding author in more than 100 SCI papers published in internationally renowned journals such as Cell, Lancet Oncology, Blood, Leukemia, etc. Professor Jin has won 2 second prizes of the National Science and Technology Progress Award and 12 Zhejiang Province Science and Technology Progress Awards as first prize and major participant

                    

Dr. Wenyu Li, Department of Lymphoma, Guangdong General Hospital

  • Main interest: Clinical and basic research of lymphoma
  • Member of ASH, CACA, Vice Chairman of association of hematologist of Guangzhou and lymphoma division of Guangzhou anti-cancer association

Dr. Li got her doctoral degree from Jinan University . She has focused on the clinical and basic research of lymphoma for about 20 years and is experienced in the treatment of lymphoma. She has applied grants from Guangdong province and China and has published more than 20 papers.

                     

Dr. Qingqing Cai, Department of Internal Medicine, Sun Yat-sen University Cancer Center

  • Deputy Director, Department of Internal Medicine,Sun Yat-sen University Cancer Center
  • Professor, Chief Physician, Doctoral supervisor
  • Lymphoma Section, Oncology Branch, Guangdong Medical Association Chairman
  • Youth Committee of Oncology Branch, Chinese Medical Association Vice-Chairman
  • China Medical Education Association lymphoma professional committee Vice-Chairman
  • Guangdong Provincial Association of Women Physicians for Lymphoma Vice-Chairman
  • Youth Committee of Guangdong Anti-Cancer Association Vice-Chairman
  • Beijing Cancer Society Lymphoma Immunity Panel Vice-Chairman
  • Published a number of SCI articles as lead author in 《Leukemia》, CCR and other magazines, presided over 3 national natural funds and a number of provincial funds

                        

Dr. Yan Xie, Department of Lymphoma, Beijing Cancer Hospital

Expertise in lymphoma diagnosis and treatment and stem cell transplantation. Participated in numerous clinical trials and has extensive clinical trial management experience


Immunotherapies for Lymphoma Treatment

Abstract #: 8005

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL)  

Abstract #: 8000

Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era? 


If you need to request a copy of the abstract, please send email to "webinars@eChinaHealth.com”.

Disclaimers: ASCO and eChinaHealth do not endorse any health care product, therapy, diagnostic test or device.

____________________________________________________________________________

Organizer:

       

Co-organizer:

                                         

Partners:

                                

Exclusive Live Streaming Platform:

                                          

Welcome

Welcome to john the ASCO China Conference WeChat Groups! You can follow up the latest on ASCO China conferences and network with fellow Chinese and global attendees. We will post the conference information including the links on recorded conference videos. Please use your WeChat to scan the QR code to join.